Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Citi
Baxter
Colorcon
Teva
Daiichi Sankyo
Cipla
Dow

Generated: April 19, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: Dr Reddys Labs Ltd

« Back to Dashboard

Dr Reddys Labs Ltd Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Dr Reddys Labs Ltd atomoxetine hydrochloride 090609 40MG CAPSULE; ORAL
Dr Reddys Labs Ltd amlodipine maleate; benazepril hydrochloride 021714 2.5MG; 10MG CAPSULE; ORAL
Dr Reddys Labs Ltd sildenafil citrate 202597 100MG TABLET; ORAL
Dr Reddys Labs Ltd lamotrigine 202383 100MG TABLET, EXTENDED RELEASE;ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
UBS
Baxter
Federal Trade Commission
Merck
Teva
Argus Health
Deloitte
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.